Kairos Pharma (KAPA) Cash from Financing Activities (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Cash from Financing Activities came in at $223000.0 in Q2 2025, up 49.66% YoY from $149000.0 in Q2 2024, and down 92.71% on a QoQ basis from $3.1 million in Q1 2025.
Kairos Pharma (KAPA) Cash from Financing Activities (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Cash from Financing Activities data on file, last reported at $223000.0 in Q2 2025.
- Quarterly Cash from Financing Activities rose 49.66% year-over-year to $223000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $8.4 million (changed N/A YoY) and the FY2025 annual result came in at $6.7 million, up 29.72% from the prior year.
- Cash from Financing Activities retreated to $223000.0 in Q2 2025, from $3.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $5.2 million in Q3 2024 to a low of -$142000.0 in Q4 2024.
- A 3-year average of $1.2 million and a median of $149000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 97.22% — and 2025, when it jumped 3535.96%.
- Tracing KAPA's Cash from Financing Activities over 3 years: stood at -$72000.0 in 2023, then sank by 97.22% to -$142000.0 in 2024, then soared by 257.04% to $223000.0 in 2025.
- The last three Cash from Financing Activities figures came in at $223000.0 (Q2 2025), $3.1 million (Q1 2025), and -$142000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 223,000.00 |
| Jun 30, 2025 | 223,000.00 |
| Mar 31, 2025 | 3.06 Mn |
| Mar 31, 2025 | 3.06 Mn |
| Dec 31, 2024 | -142,000.00 |
| Dec 31, 2024 | -142,000.00 |
| Sep 30, 2024 | 5.22 Mn |
| Sep 30, 2024 | 5.22 Mn |
| Jun 30, 2024 | 149,000.00 |
| Jun 30, 2024 | 149,000.00 |
| Mar 31, 2024 | -89,000.00 |
| Mar 31, 2024 | -89,000.00 |
| Dec 31, 2023 | -72,000.00 |
| Dec 31, 2023 | -72,000.00 |